Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Werewolf Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 71 | 1 | 69 | −1 |
| Shares | 32.5M | 1.59M | 32.2M | +1.32M (+4.3%) |
| Value | $79.2M | $3.87M | $68.3M | −$7.07M (−9.4%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,637,050 | $3.47M | 0.00% |
| SEI Investments Co | 21,322 | $45.2K | 0.00% |
| XTX Topco Ltd | 21,209 | $45.0K | 0.00% |
| Deutsche Bank AG | 18,454 | $39.1K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 17,111 | $36.3K | 0.00% |
| Regal Investment Advisors LLC | 14,459 | $30.7K | 0.00% |
| SG Americas Securities, LLC | 13,517 | $29.0K | 0.00% |
| Engineers Gate Manager LP | 11,777 | $25.0K | 0.00% |
| Nisa Investment Advisors, LLC | 125 | $265 | 0.00% |
| Russell Investments Group, Ltd. | 86 | $182 | 0.00% |
| Sterling Capital Management LLC | 81 | $172 | 0.00% |
| Capital Performance Advisors LLP | 60 | $127 | 0.00% |
| CWM, LLC | 192 | $0 | 0.00% |
Sold out (14)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Verition Fund Management LLC | 233,828 | $570.5K |
| HRT Financial LP | 197,377 | $481.0K |
| Janus Henderson Group PLC | 167,987 | $406.5K |
| Marshall Wace, LLP | 134,184 | $327.4K |
| Royce & Associates LP | 125,484 | $306.2K |
| Murchinson Ltd. | 62,500 | $152.5K |
| Man Group plc | 44,481 | $108.5K |
| Alpine Global Management, LLC | 37,551 | $91.6K |
| Boothbay Fund Management, LLC | 37,500 | $91.5K |
| Cubist Systematic Strategies, LLC | 28,371 | $69.2K |
| Jump Financial, LLC | 21,099 | $51.5K |
| Balyasny Asset Management LLC | 10,459 | $25.5K |
| Paloma Partners Management Co | 10,043 | $24.5K |
| Qube Research & Technologies Ltd | 8,315 | $20.3K |
Not filed for Q3 2024 yet (1)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 1,587,724 | $3.87M |